The systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trial

Basit Öğe Kaydı
dc.authoridDuygu Koyuncu Irmak / 0000-0002-3277-5535en_US
dc.authoridErdal Karaöz / 0000-0002-9992-833Xen_US
dc.authorscopusidDuygu Koyuncu Irmak / 57219539042
dc.authorscopusidErdal Karaöz / 7003448087
dc.authorwosidErdal Karaöz / IXE-6677-2023
dc.contributor.authorAdaş, Gökhan
dc.contributor.authorÇukurova, Zafer
dc.contributor.authorKart Yaşar, Kadriye
dc.contributor.authorYılmaz, Rabia
dc.contributor.authorIşıksaçan, Nilgün
dc.contributor.authorKasapoğlu, P.
dc.contributor.authorYeşilbağ, Zuhal
dc.contributor.authorKoyuncu Irmak, Duygu
dc.contributor.authorKaraöz, Erdal
dc.date.accessioned2021-07-05T11:29:07Z
dc.date.available2021-07-05T11:29:07Z
dc.date.issued2021en_US
dc.departmentİstinye Üniversitesi, Tıp Fakültesi, Temel Tıp Bilimleri Bölümüen_US
dc.description.abstractThe aim of this clinical trial was to control the cytokine storm by administering mesenchymal stem cells (MSCs) to critically-ill COVID-19 patients, to evaluate the healing effect, and to systematically investigate how the treatment works. Patients with moderate and critical COVID-19 clinical manifestations were separated as Group 1 (moderate cases, n = 10, treated conventionally), Group 2 (critical cases, n = 10, treated conventionally), and Group 3 (critical cases, n = 10, treated conventionally plus MSCs transplantation therapy of three consecutive doses on treatment days 0, 3, and 6, (as 3 × 106 cells/kg, intravenously). The treatment mechanism of action was investigated with evaluation markers of the cytokine storm, via biochemical parameters, levels of proinflammatory and anti-inflammatory cytokines, analyses of tissue regeneration via the levels of growth factors, apoptosis markers, chemokines, matrix metalloproteinases, and granzyme-B, and by the assessment of the immunomodulatory effects via total oxidant/antioxidant status markers and the levels of lymphocyte subsets. In the assessment of the overall mortality rates of all the cases, six patients in Group-2 and three patients in Group-3 died, and there was no loss in Group-1. Proinflammatory cytokines IFN?, IL-6, IL-17A, IL-2, IL-12, anti-inflammatory cytokines IL-10, IL-13, IL-1ra, and growth factors TGF-?, VEGF, KGF, and NGF levels were found to be significant in Group-3. When Group-2 and Group-3 were compared, serum ferritin, fibrinogen and CRP levels in Group-3 had significantly decreased. CD45 +, CD3 +, CD4 +, CD8 +, CD19 +, HLA-DR +, and CD16 + / CD56 + levels were evaluated. In the statistical comparison of the groups, significance was only determined in respect of neutrophils. The results demonstrated the positive systematic and cellular effects of MSCs application on critically ill COVID-19 patients in a versatile way. This effect plays an important role in curing and reducing mortality in critically ill patients.en_US
dc.identifier.citationAdas, G., Cukurova, Z., Yasar, K. K., Yilmaz, R., Isiksacan, N., Kasapoglu, P., Yesilbag, Z., Koyuncu, I. D., & Karaoz, E. (2021). The Systematic Effect of Mesenchymal Stem Cell Therapy in Critical COVID-19 Patients: A Prospective Double Controlled Trial. Cell transplantation, 30, 9636897211024942. https://doi.org/10.1177/09636897211024942en_US
dc.identifier.doi10.1177/09636897211024942en_US
dc.identifier.pmid34180719en_US
dc.identifier.scopus2-s2.0-85109747004en_US
dc.identifier.scopusqualityN/Aen_US
dc.identifier.urihttps://doi.org/10.1177/09636897211024942
dc.identifier.urihttps://hdl.handle.net/20.500.12713/1875
dc.identifier.wosWOS:000688492300001en_US
dc.identifier.wosqualityQ2en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.institutionauthorKoyuncu Irmak, Duygu
dc.institutionauthorKaraöz, Erdal
dc.language.isoenen_US
dc.publisherSage Journalsen_US
dc.relation.ispartofCell Transplantationen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/openAccessen_US
dc.subjectCOVID-19en_US
dc.subjectCytokinesen_US
dc.subjectGrowth Factorsen_US
dc.subjectMesenchymal Stem Cellen_US
dc.titleThe systematic effect of mesenchymal stem cell therapy in critical COVID-19 patients: a prospective double controlled trialen_US
dc.typeArticleen_US

Dosyalar

Orijinal paket
Listeleniyor 1 - 1 / 1
Küçük Resim
İsim:
65.pdf
Boyut:
331.55 KB
Biçim:
Adobe Portable Document Format
Açıklama:
Tam Metin / Full Text
İndir
Lisans paketi
Listeleniyor 1 - 1 / 1
Küçük Resim Yok
İsim:
license.txt
Boyut:
1.44 KB
Biçim:
Item-specific license agreed upon to submission
Açıklama:
İndir

Koleksiyon

PubMed İndeksli Yayınlar Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu
Temel Tıp Bilimleri Bölümü Makale Koleksiyonu
WoS İndeksli Yayınlar Koleksiyonu